Daptomycin
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Daptomycin: From Gram-Positive Bacterial Infections to Osteoarthritis
One-Sentence Summary
Daptomycin is an intravenous cyclic lipopeptide antibiotic used against Gram-positive bacterial infections such as skin infections, bacteremia and right-sided endocarditis. The TxGNN model predicts it may be effective for osteoarthritis, but there are 0 clinical trials and only 9 publications, all on bone and joint infections rather than degenerative osteoarthritis. The high score most likely reflects knowledge-graph proximity to “osteoarticular” terms, not a real anti-osteoarthritis effect.
Quick Overview
| Item | Content |
|---|---|
| Predicted New Indication | Osteoarthritis |
| TxGNN Prediction Score | 99.86% |
| Evidence Level | L4 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 (NDA/ANDA) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Daptomycin is a cyclic lipopeptide that depolarizes the membranes of Gram-positive bacteria. Detailed mechanism-of-action data is not available in the Evidence Pack.
The relationship between the original and predicted indication is weak. Osteoarthritis is a degenerative disease driven by cartilage breakdown and low-grade joint inflammation, and daptomycin’s antibacterial action has no known link to it.
All retrieved papers concern bone and joint infections, such as prosthetic joint infection and septic arthritis, treated with daptomycin. That is a different disease from degenerative osteoarthritis. The prediction most likely comes from term proximity in the knowledge graph rather than from a genuine therapeutic signal.
Among the other predictions, rheumatoid arthritis (rank 2) has the only preclinical signal. A 2025 study (PMID 39571268) reported that daptomycin reduced collagen-induced arthritis in mice via suppression of inflammatory cytokines and NF-κB signaling. There is no human data, and this is a separate research question from osteoarthritis.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 23519823 | 2013 | Cohort | Int Orthop | Safety and efficacy of high-dose daptomycin plus rifampicin in Gram-positive osteoarticular infections |
| 22511636 | 2012 | Cohort | J Antimicrob Chemother | Clinical efficacy and safety of daptomycin in hip and knee periprosthetic joint infections |
| 26235888 | 2015 | Cohort | Int J Antimicrob Agents | High-dose daptomycin (>6 mg/kg) in complicated bone and joint and implant-associated infections (no abstract available) |
| 17999973 | 2008 | Cohort | J Antimicrob Chemother | Daptomycin vs standard therapy for osteoarticular infections associated with S. aureus bacteremia |
| 21477701 | 2010 | Cohort (registry) | Med Clin (Barc) | Spanish data from the EU-CORE registry of routine daptomycin use in Gram-positive infections |
| 23312602 | 2013 | Survey | Int J Antimicrob Agents | Survey of current prosthetic joint infection management among infectious disease physicians |
| 25650692 | 2015 | Cohort | Surg Infect | Ten-year evolution of staphylococcal profiles in osteoarticular infections |
| 22854340 | 2012 | In vitro | J Antibiot | Antibiotic susceptibility of S. aureus and S. epidermidis from prosthetic joint infections |
| 32206362 | 2020 | Case report | Case Rep Orthop | Chronic Corynebacterium striatum septic arthritis in a patient with osteoarthritis referred for knee arthroplasty |
None of these studies tests daptomycin as a treatment for degenerative osteoarthritis. The 2020 case report only mentions osteoarthritis as the patient’s background diagnosis.
US Market Information
The Evidence Pack lists 20 authorizations in total. The first five are shown below. Approved indication text is not included in the records.
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| ANDA217215 | Daptomycin | Lyophilized powder for injection (solution) | Biocon Pharma Inc. |
| NDA217415 | Daptomycin | Lyophilized powder for injection (solution) | Xellia Pharmaceuticals USA LLC |
| ANDA207104 | Daptomycin | Lyophilized powder for injection (solution) | Sagent Pharmaceuticals |
| ANDA216445 | Daptomycin | Lyophilized powder for injection (solution) | NorthStar Rx LLC |
| ANDA208375 | Daptomycin | Lyophilized powder for injection (solution) | BluePoint Laboratories |
All available forms are injectable: lyophilized powder for solution or suspension, and ready-to-use solution.
Safety Considerations
Please refer to the package insert for safety information.
- Adverse-event signal: One case report (PMID 36693494) describes daptomycin-induced rhabdomyolysis followed by acute gouty arthritis. Muscle injury is a known concern with this drug.
- Practical constraint: IV-only dosing is a poor fit for a chronic condition like osteoarthritis.
Conclusion and Next Steps
Decision: Hold
Rationale: There are no clinical trials, and the literature covers joint infections rather than osteoarthritis. The high TxGNN score is likely an artifact of term proximity, so the osteoarthritis prediction lacks a mechanistic basis.
To proceed, the following is needed:
- Mechanism-of-action data from DrugBank
- Package insert warnings and contraindications, which are currently missing and block safety screening
- Preclinical evidence of daptomycin activity in degenerative osteoarthritis models, if the direction is pursued at all
- Consideration of redirecting the effort to the rheumatoid arthritis hypothesis (PMID 39571268), which has a preclinical signal and would need translational work
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.